6/19/2014 10:23:51 AM
CORAL GABLES, FL,
Partners, Inc. (Nasdaq:
that the Company will be presenting at
Patrick J. McEnany, Catalyst’s Chief Executive Officer
Steven Miller, Ph.D.
ompany and its key programs
. The Company’s
will be available on
the “Investors” section of the Company’s website,
following the presentation.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the
development and commercialization of prescription drugs targeting rare (orphan) neuromuscular
and neurological diseases, including Lambert
Eaton Myasthenic Syndrome
spasms, and Tourette Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of
LEMS, is currently undergoing testing in a global, multi
center, pivotal phase 3 trial and has
received Breakthrough Therapy Designation from the U.
and Drug Administration
Catalyst is also developing a potentially safer and more potent vigabatrin analog
115) to treat infantile spasms, and epilepsy, as well as other neurological
conditions associated with reduced GABAergi
c signaling, like post
traumatic stress disorder and
115 has been granted U.S. orphan drug designation for the treatment
of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation
for the treatment
of West Syndrome by the European Commission.
David Connolly or Aurora Krause
Patrick J. McEnany
Catalyst Pharmaceutical Partners, Inc.
Chief Executive Officer
Help employers find you! Check out all the jobs and post your resume.
comments powered by